Aspire BioPharma is trading 11.4% higher at $6.25, staging a recovery after a sharp 22.6% drop to $5.61 on July 29, 2026.
- The move appears driven by a technical bounce and bargain-hunting amid thin liquidity rather than new fundamental news or company-specific catalysts.
- Broader markets are also trading modestly higher as risk sentiment stabilizes, providing additional support for the rebound.